Last reviewed · How we verify
Fluad_MF59-adjuvanted trivalent influenza subunit vaccine
Fluad_MF59-adjuvanted trivalent influenza subunit vaccine is a Biologic drug developed by Novartis Vaccines. It is currently FDA-approved.
Fluad, an MF59-adjuvanted trivalent influenza subunit vaccine marketed by Novartis Vaccines, holds a significant position in the influenza vaccine market. Its key strength lies in the MF59 adjuvant, which enhances immune response, potentially offering better protection against influenza compared to non-adjuvanted vaccines. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic manufacturers.
At a glance
| Generic name | Fluad_MF59-adjuvanted trivalent influenza subunit vaccine |
|---|---|
| Sponsor | Novartis Vaccines |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluad_MF59-adjuvanted trivalent influenza subunit vaccine CI brief — competitive landscape report
- Fluad_MF59-adjuvanted trivalent influenza subunit vaccine updates RSS · CI watch RSS
- Novartis Vaccines portfolio CI